Amphetamine-Related Disorders
35
0
1
20
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 35 trials
100.0%
+13.5% vs benchmark
3%
1 trials in Phase 3/4
10%
2 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (35)
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
Hospital-Based Contingency Management
Treatment Effect of Cross-frequency Transcranial Alternating Current Stimulation on the MUD
Computerized Exercise to Alter Stimulant Approach Responses
Implementation and Effectiveness of Multidiscipline-Integrated Addiction Treatment Model
Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)
Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)
Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)
Ondansetron for the Treatment of Methamphetamine Dependence - 1
Tyrosine for Methamphetamine Dependence - 1
Bupropion for the Treatment of Methamphetamine Dependence - 1
To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1
Effects of Stimulant Dependence on Human Striatal Dopamine System - 15
Cognitive Correlates of Substance Abuse, Part 2 - 16
Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1
A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1
Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
Cognitive Correlates of Substance Abuse - 11
Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1